{"id":"NCT04739306","sponsor":"Celltrion","briefTitle":"Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema","officialTitle":"A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-07-22","primaryCompletion":"2022-10-14","completion":"2023-04-24","firstPosted":"2021-02-04","resultsPosted":"2023-12-05","lastUpdate":"2023-12-05"},"enrollment":348,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema (DME)"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P42","otherNames":[]},{"type":"BIOLOGICAL","name":"Eylea","otherNames":[]}],"arms":[{"label":"CT-P42","type":"EXPERIMENTAL"},{"label":"Eylea","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema","primaryOutcome":{"measure":"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"CT-P42","deltaMin":9.43,"sd":0.798},{"arm":"Eylea","deltaMin":8.85,"sd":0.775}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Slovakia"]},"refs":{"pmids":["40879891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":174},"commonTop":["Diabetic retinal oedema","Hypertension","COVID-19","Diabetes mellitus inadequate control","Nasopharyngitis"]}}